Last reviewed · How we verify
NCT06373913: PCSK9
The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom
trial in Hyperlipidemias in 75 participants. Currently enrolling.
30 July 2027
Quick facts
| Lead sponsor | Kolding Sygehus |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 1 June 2023 |
| Primary completion | 30 July 2027 |
| Estimated completion | 30 July 2028 |
| Sites | 1 location across Denmark |
Conditions studied
- Hyperlipidemias — all drugs for Hyperlipidemias →
- Nephrotic Syndrome — all drugs for Nephrotic Syndrome →
Sponsor
Kolding Sygehus — full company profile →
Who can join
18 and older, any sex, with Hyperlipidemias or Nephrotic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nephrotic syndrome (NS) is characterized by gross proteinuria (\>3.5 g/day), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased morbidity and mortality. The study aim is to investigate the role of the protein convertase subtilisin/kexin type 9 (PCSK9) in hyperlipidemia of NS, which has been suggested to play an important role. This is done by testing the following hypotheses: 1. PCSK9 is increased in patients with NS and hyperlipidemia compared to kidney-healthy controls 2. The level of PCSK9 in plasma correlates to the degree of proteinuria. 3. PCSK9 i increased in the kidney tissue of patients with NS The study will compare plasma levels of PCSK9 in correlation with degree of protein in the urine between test persons with NS and kidney healthy controls. Furthermore the investigators will study the the degree of PCSK9 in the kidney in biopsies obtained from test persons with nephrotic syndrome and test persons without proteinuria.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06373913
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperlipidemias
Currently open trials in the same condition.
- NCT06903897 — Social Needs Screening and Chronic Diseases Study (WE CARE) · NA · recruiting
- NCT06049420 — Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients · NA · recruiting
- NCT06461273 — Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome · NA · active not recruiting
- NCT06094491 — Virtual Diabetes Group Visits Across Health Systems · Phase 2 · active not recruiting
- NCT06055036 — Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention · NA · recruiting
Other Kolding Sygehus trials
Trials by the same sponsor.
- NCT06631378 — Transverse Versus Longitudinal Groin Incision in Vascular Surgery · NA · recruiting
- NCT06642402 — Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles · recruiting
- NCT04574336 — Scandinavian Humeral Diaphyseal Fracture Trial · NA · recruiting
- NCT04734795 — The Prevalence of Dysfunctional Breathing in Children and Adolescents With Asthma · completed
- NCT04424186 — 'Rehabilitation for Life' · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06373913 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kolding Sygehus
- Last refreshed: 9 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06373913.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing